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MESSAGE FROM    
THE DIRECTOR 
Dr. Don St. Germain 
Dear Friends, 
 
Each year as the foliage is starting to garner our attention and as our fiscal year is coming to a close, I give a State of 
the Institute presentation to our faculty and staff.  The presentation focuses on institutional and individual successes, 
opportunities going forward, and challenges old and new.  Not surprisingly, part of the presentation is a report on the 
grant funding the Institute has received during the prior 12 months.  It is the nature of our business that extramural 
funding ebbs and flows from month to month and year to year as new grants are awarded and older ones expire.      
Thus, there are good years and there are lean years — and then there is 2017.   
 
The year just ended is the most remarkable funding year in the history of MMCRI.  Through the hard work of our  
investigators, technical staff, administrative staff, and collaborators, MMCRI was awarded over $39 million in grants 
in 2017.  These funds will serve to support our research activities with the goals of improving the care of our patients 
and our communities and advancing the science of medicine.  Much of this funding came from two large federal 
grants of $20 million and $11 million, and three awarded by foundations/non-profit organizations. 
 
This funding will advance research in chronic diseases such as cardiovascular, addiction, aging, and cancer, as well as 
metabolic diseases that include obesity and diabetes.  In my recent address, I was anxious to acknowledge the       
principal investigators and research teams responsible for those major awards.  But prior to that celebration, I chose 
to recognize one of our junior investigators, Michaela Reagan, and our Vector-borne Laboratory for their                      
accomplishments in being awarded the smallest grants in 2017, each for about $2,000.  Although comparably small in 
amount, each grant grew out of the same scientific drive, intellectual curiosity and dedication shown by those     
working on the largest grants in our portfolio.  Each award, no matter the size, better positions us to accomplish our 
mission.  
 
The pages that follow highlight the work underway from these research awards, and much more. I hope you enjoy 
taking a closer look at the research and the individuals taking on this exciting work.   I extend my admiration and   
congratulations to all for helping make 2017 a year of wonderful accomplishments. 
 
Sincerely, 
 
Don St. Germain, MD, Director & Vice President of Research 
Maine Medical Center Research Institute 
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2017 FAST FACTS 
MMCRI At A Glance 
180 Staff Members 
$39 Million Grants Awarded 
200+ Clinical Trial Studies  
255 Scientific Publications 
12 Core Facilities with State   
of the Art Equipment (see in 
depth story, page 5) and            
BioBank Tissue Repository with 
Over 100,000 Human    
Tissue Samples Distributed 
 
Executive Administration 
Donald St. Germain, MD  
Director & VP Research 
 
Rick McAllister, MEd 
Senior Director, Research Administration 
2017 Sources of Research Support 
By Sponsor Type 
Center Leadership 
Thomas Gridley, PhD 
Interim Director, Center for Molecular Medicine 
 
Paul Han, MD, MA, MPH 
Director, Center for Outcomes Research & Evaluation 
 
Susan Santangelo, ScD 
Director, Center for Psychiatric Research 
 
Clifford Rosen, MD 
Director, Center for Clinical & Translation Research 
 
For a full list of Principal Investigators, Affiliated Faculty, and 
Staff, please visit our website,  www.mmcri.org 
2017 Leadership 
Above:  81 Research Drive, Scarborough, Maine. 
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Center for Molecular Medicine 
BENCH—BASIC RESEARCH 
Funding from NIH Helps Build         
Research Excellence in Understanding 
Causes of Metabolic Disease 
It was an exciting 
summer for 
MMCRI; on the 
heels of a NIH $20 
million award (see 
details page 6), the 
Institute was   
awarded a five-year, 
$11 million Center 
of Biomedical    
Research Excellence 
(COBRE) grant also 
by the National Institutes of 
Health. This funding will establish 
a multidisciplinary research center 
at MMCRI to model the basis of human metabolic diseases. This 
program includes partnerships between Maine Medical Center 
and the University of Maine, the University of New England and 
Brown University.  
 
The COBRE program is led by Dr. Lucy Liaw, Associate Director 
of the Center for Molecular Medicine, with support from Dr. Cliff 
Rosen, Director of The Center for Clinical & Translational     
Research at MMCRI, and Dr. Irwin Brodsky, Maine Medical    
Partners Endocrinologist and Clinical Advisor.  The overall goal is 
to address obesity, osteoporosis and diabetes – all metabolic      
diseases common in Maine – by understanding pathways that lead 
to these disorders.  
 
“One feature of this COBRE award is that it supports young    
investigators as they embark upon independent research projects,” 
says Dr. Liaw. The COBRE award provides funding to four young 
investigators (see infographic, right) to conduct cellular, molecular, 
biochemical and clinical research. Dr. Liaw adds, “We have      
established a network of mentors and consultants to provide 
strong support for these investigators as they launch their careers. 
Fostering and maintaining talent in Maine is crucial for the 
growth of biotechnology in our state.”  
 
The award also supports the expansion of state-of-the-art           
technology, including advanced protein and lipid analysis and 
bone measurements, and the assessment of physiology and body 
metabolism.  For more details and progress of the metabolic    
COBRE:  www.mmcri.org/metabolic_cobre. 
Dr. Lucy Liaw, Director of the COBRE 
in Metabolic Networks 
Tom Gridley, PhD, Interim Director 
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AARON BROWN, PhD &  
LEIF OXBURGH, DVM, PhD 
Culture conditions for expansion of nephron          
progenitor cells  
 
       VOLKHARD LINDNER, MD, PhD 
         Kit for detecting Cthrc1 in a sample  
 
PATENTS 
Center for Molecular Medicine 
BENCH—BASIC RESEARCH Tom Gridley, PhD, Interim Director 
Drs. Peter Brooks, Sergey Ryzhov, and Arturo 
Hernandez in the Center for Molecular Medicine 
all were successful in obtaining new federal grant 
funding this past year to support innovative    
research projects.  
Cancer & the Immune System 
Peter Brooks, PhD 
Peter Brooks is a cancer researcher with new  
funding from both the National Institutes of 
Health (NIH) and the Department of Defense 
(DOD). Both projects focus on the immune    
system and developing potential therapeutics that 
may help the body activate its natural immune cells to 
detect and destroy tumor cells. The DOD project focuses 
on ovarian cancer, which has been difficult to treat with  
current immunotherapies. The Brooks lab discovered 
that a cancer-specific fragment of collagen seems to allow    
ovarian cancer cells to hide from immune cells, and they 
have developed a specific antibody that can bind and 
block this collagen fragment. The project will test    
whether this antibody can thus “reactivate” immune   
control of ovarian cancer and assist in anti-cancer       
therapies. The NIH project focuses on malignant        
melanoma, for which the survival rate is still low, despite 
treatment. This laboratory research is critical in the    
development of new, targeted therapies with the potential 
to improve the health outcomes of cancer patients.  
Heart Disease 
Sergey Ryzhov, PhD 
Dr. Ryzhov is also studying the body’s natural immune 
system, in the context of heart disease.  Myocardial     
infarction, or a heart attack, happens to someone in the 
United States every 40 seconds. This NIH funded project 
studies the growth factor neuregulin and its interaction 
with its receptor, ERBB3. The Ryzhov lab discovered that 
this signaling axis controls the shift of inflammatory cells 
from a pro-inflammatory state to a pro-resolution state. 
Early after myocardial infarction, immune cells infiltrate 
to repair the heart tissue, but need to be shut down to 
avoid chronic inflammation. The lab has identified    
neuregulin as a factor that can promote resolution of 
inflammation, which could partly explain why neuregulin 
provides a beneficial effect following myocardial         
infarction. 
Left to right: Arturo Hernandez, Sergey Ryzhov, and Peter Brooks 
Thyroid & Genetics 
Arturo Hernandez, PhD 
Dr. Hernandez studies the consequences of thyroid hormone 
alterations during the developmental period for                
neuroendocrine and neurological function in later life. His 
lab focuses on the type 3 deiodinase (Dio3), a critical        
enzyme that limits the levels of exposure to thyroid hormone. 
The recently awarded NIH grant is based on the finding that 
a developmental overexposure to thyroid hormone leads to 
neurological abnormalities not only in the individuals        
affected, but also in their unexposed descendants due to 
mechanisms of transgenerational epigenetic inheritance. 
Some of the neurological  abnormalities observed include 
aberrant brain morphology and cytoarchitecture,               
hydrocephalus and altered mood and social behavioral     
profiles of relevance to human conditions like anxiety,      
depression, attention deficit and hyperactive disorder, autism 
and schizophrenia. This work may partly explain the         
unidentified heritable etiology of some of these conditions 
and lead to novel epigenetic-based clinical tools for risk     
assessment, prevention and response to clinical treatment. 
 
New Federal Research 
Grants:  Cancer, Heart, &              
Endocrine Disease 
 7 
 
“Our Core feels like more of a collaboration than a 
service,” says Victoria DeMambro, Manager for       
Principal Investigator Cliff Rosen’s Physiology Core 
Facility at MMCRI. This atmosphere of                
collaboration brings her and her colleagues a       
tremendous amount of satisfaction in their efforts 
to provide researchers with comprehensive, in-house 
metabolic and cellular phenotyping of mouse 
strains. 
 
The Physiology Core at MMCRI, established in 
2012, was championed by Dr. Rosen and others, 
and developed initially in response to a new       
demand in the field of Stem Cell Biology that    
researchers move from cell-based assays to mouse 
models to study changes in whole organism       
physiology. With a focus on assessing metabolic 
phenotypes for novel mouse models of  human  
disease, analyses from this core facility provide insight into 
“on target” and “off  target” tissue phenotypes, and     
increase our understanding of the physiological           
implications of changes in regulators of stem and        
progenitor cell formation.  
 
To complement assays for biochemical markers of skeletal 
and soft tissue metabolism, sixteen high-tech Promethion 
metabolic mouse cages (like the one behind DeMambro 
pictured above) provide eighty-seven distinct readings on 
each mouse per second - collected over the course of about 
five days per experiment - on mouse activity, body        
composition, oxygen consumption, CO2 production, heat 
production, physical and behavioral profiles, and diet and 
fluid intakes.  
 
The Physiology Core provides this real-time data on    
metabolic  phenotypes to fully complement other        
biochemical studies for comprehensive hematological, 
metabolic, and skeletal phenotyping. This output is     
coupled with dual energy X-ray absorptiometry/NMR 
analysis that measures in vivo body  composition in a cross
High-Tech & Collaboration are Key Elements to         
Physiology Core Success 
-sectional or longitudinal manner.  A recently up-graded Seahorse 
XFe96 analyzer provides advanced cellular and mitochondrial        
bioenergetics data, to quantify oxidative phosphorylation and        
glycolysis in cells and tissues. 
 
DeMambro notes many sources of   
satisfaction and success from the     
Physiology Core.  Most important 
among these are being able to      
provide help to numerous new and  
established researchers who go on to 
publish their work, and helping a    
number of early-career investigators 
begin to acquire their own research 
funding. Her enthusiasm is high around 
the Core’s role in supporting MMCRI’s new COBRE in               
Mesenchymal and Neural Regulation of Metabolic Networks grant 
projects – each of which is led by an early-career MMCRI researcher. 
For more information on MMCRI’s 12 core facilities and services, 
please visit our website:  www.mmcri.org. 
71 
Publications from the 
Center of Molecular 
Medicine in 2017. 
Above:  Vicki DeMambro prepares for an experiment to monitor                
comprehensive metabolic and behavioral features in mice.  
Noteworthy  
EVENTS 
 
RESEARCH RETREAT – MAY 3, 2017  
MMCRI and Maine Medical Center coordinated a            
multidisciplinary biomedical research symposium,   
bringing together more than 200 physicians, nurses, 
health care providers, scientists and trainees from 
over 15 hospital departments, as well as affiliate   
institutions in Maine, and from neighboring states in 
New England.  
 
SEMINAR SERIES  
MMCRI hosted 20 seminar guests in 2017. 
 
DATA REVIEW SERIES  
MMCRI graduate students, postdoctoral trainees, 
Staff Scientists, and Core Directors delivered 32 Data       
Review Sessions for their colleagues in 2017. 
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Center for 
Clinical & Translational Research 
BEDSIDE—CLINICAL & TRANSLATIONAL RESEARCH 
$20M from NIH Will Establish    
Northern New England Clinical &                 
Translational Research Network 
Dr. Gary Stein, University of Vermont (left) and Dr. Cliff Rosen 
(right) briefed Senator Susan Collins on the NNE-CTR award.   
In July, the National Institutes of Health (NIH)/National 
Institute of General Medical Sciences (NIGMS) awarded a 
five-year, $20 million research grant to Maine Medical 
Center and its partnering institutions, the University of 
Vermont and the University of Southern Maine, to       
establish the Northern New England Clinical and      
Translational Research Network (NNE- CTR), a             
consortium dedicated to enhancing collaborative         
biomedical research activities for the improvement of   
human health. This consortium joins nine other 
NIGMS supported regional networks across the  
country.  
 
Clifford Rosen, MD,     
Director of the Center 
for Clinical and     
Translational    
Research at 
MMCRI, and Gary 
Stein PhD, Director 
of the   University of 
Vermont Cancer Center, 
will co-lead the program 
along with Program               
Coordinators, Thomas 
Gridley, PhD, (MMCRI) 
and Gordon L. Jensen, 
MD, PhD, (UVM). 
 
Collaborations with researchers at Tufts University School of 
Medicine and the Geisel School of Medicine at Dartmouth will 
serve to extend the capabilities of the network and its reach across 
the region.  
 
The NNE-CTR aims to help researchers develop and implement 
innovative medical treatments for many chronic diseases        
prevalent in our region including cancer, heart disease, obesity, 
diabetes, Alzheimer’s disease and substance abuse.  Research  
activities will also focus on defining optimal methods of disease 
prevention and health care delivery in rural environments, where 
approximately 60 percent of Maine’s population resides.   
 
The network will also train the next generation of biomedical 
scientists, physicians and nurses in research methodology to   
attract additional research support to the region.  
 
Cliff Rosen, MD, Director 
54 
MMC BioBank is one of only 54  
biorepositories nationwide to     
receive College of American 
Pathologists (CAP) Accreditation. 
The BioBank received its             
recertification in September 2017. 
Such initiatives are critical in meeting the healthcare needs of 
the region’s aging population in an era when ground-
breaking medical treatments are rapidly being developed.  
 
“Our goal is to support innovative and transformative         
research, increase participation in clinical research and        
improve access of our rural residents to clinical studies. This 
will ultimately improve the health and vitality of the people 
of Maine,  Vermont, and New Hampshire,” said Dr. Rosen.  
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Clinical Investigator Spotlight: Dr. David Seder 
200+ 
Clinical Trial Studies in 
2017 at MMCRI. 
Vector-borne Disease Lab 2017 Update  
Director, Robert Smith, MD, MPH 
 
Figure 1. Municipalities in Maine sampled               
during the mosquito surveillance by MMCRI-          
related surveys (Blue) or ME Department             
of Agriculture, Conservation, and Forestry   
(DACF) surveys (Green). 
As climate change disrupts ecological systems, 
established patterns of disease transmission by 
ticks and mosquitos change. In collaboration 
with the Maine Centers for Disease Control, the 
Vector-borne Disease Laboratory (VBDL) at 
MMCRI (with our vector ecologist Charles 
Lubelczyk as Project Leader)  developed a      
program with two research initiatives:                
1) creation of a statewide surveillance program 
for mosquito-borne viruses, and 2) development 
of a mosquito-rearing facility, to be used for the 
monitoring of pesticide resistance in mosquitoes.  
 
Mosquito-borne West Nile virus and Eastern 
Equine Encephalitis are emerging in Maine, with 
cases, including one fatality, reported for the  
first time in our state during recent years.      
Collaborations with several University of Maine 
campuses as well as Acadia National Park and 
the University of Southern Maine (Fig. 1) employ 
students as field technicians, giving some their 
first experience in the fields of public health and 
eco-epidemiology.  
 
The VBDL’s current research on tick borne       
diseases includes risk projection based upon  
climate change, studies on newly recognized 
agents of disease transmitted by deer ticks, and 
evaluation of a new diagnostic methodology for 
Lyme disease. 
By 2050, Maine is expected to be approximately 
2°C warmer and 5–10% wetter than present. 
Research associate and University of Maine PhD 
candidate Susan Elias has gathered data to test 
the hypothesis that Lyme disease in Maine is 
associated with warm winters and humid      
summers, in addition to focal high white-tailed 
deer density, presence of invasive plant species, 
and suburbanization.  
 
Dr. Rebecca Robich and Margaret Welch    
completed a survey of the presence of deer tick 
virus in Maine. The VBDL is seeking to better 
understand the ecological factors and human 
risk factors that can lead to rare but devastating 
human infections by this virus, which caused the 
death of a woman in the Midcoast area.    
 
In collaboration with Dr. Peter Krause of Yale 
School of Public Health, Dr. Robert P. Smith,  
VBL Director, continued a multi-year study to 
better understand the pathogenesis and clinical 
spectrum of tick-borne babesiosis and of a newly 
recognized agent of relapsing fever, Borrelia      
miyamotoi.    
 
On the Lyme disease front, the lab initiated a 
pilot project on the use of a novel diagnostic test   
for early Lyme disease. Our collaborators for this 
project include the Division of Infectious       
Diseases at Johns Hopkins and an 
independent biotech company.  
Lastly, if you’d like to read a         
historical journey, check out the 
VBDL’s co-founder Pete Rand’s  
memoir, Of Ticks and Islands, which 
provides a lively and personal      
account of our early adventures in 
the field. 
SETPOINT2 is an international, multi-site     
clinical trial to improve outcomes for patients 
who have suffered a severe stroke by assessing 
the best timing of tracheostomies.  Heading this 
study is Dr. David Seder, the US Principal       
Investigator (Maine Medical Center), along with 
Dr. Julian Bösel, the German Principal           
Investigator (University of Heidelberg).  
 
The SETPOINT2 study findings could benefit 
patients because the timing of a tracheostomy 
may affect the amount of sedating medications 
that is required, and could affect brain recovery 
and the body’s ability to return to pre-stroke   
activities. Preliminary studies suggest it could be 
beneficial to perform a reversible tracheostomy 
procedure earlier than is usually done after  
severe stroke (within the first 5 days) as opposed 
to delaying more than 10 days before           
performing the procedure. This $2.6 million 
dollar research grant was awarded by the Patient      
Centered Outcomes Research Institute 
(PCORI).  The name SETPOINT2 stands for 
Stroke-Related Early Tracheostomy vs          
Prolonged Orotracheal Intubation in          
Neurocritcal Care Trial2. 
The SETPOINT2 study is      
committed to keeping patients 
informed as well as               
incorporating their insight for 
the research.  Through the 
study’s website —
(www.setpoint2.org) and         
quarterly newsletter, patients 
and site  investigators can learn 
more about the study and its 
progress.  In addition, both the US and German 
lead sites have Research Advisory Committees 
(RAC) that meet biannually.  Each RAC is made up  
of former patients, caregivers, research                
coordinators, program managers, clergy, and other 
community support members to review the study’s 
progress and give insight to help shape the research 
program moving forward. 
 
“The RAC is paramount for improving our study 
and patient outcomes,” says Seder.  “I am excited 
about the study’s progress and are looking forward 
to enrolling more patients at our 24 sites across the 
US and Germany.” 
Above: The US RAC meeting  was 
held at Maine Medical  Center in 
December. Dr. Seder, Principal      
Investigator (back row, third from 
right). 
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Center for 
Psychiatric Research 
BEDSIDE—PSYCHIATRIC RESEARCH 
First of its kind, SPARK Northern New England received funding April 2017 
The major focus of the Center for Psychiatric Research is       
on uncovering the biological underpinnings of psychiatric    
disease and behavioral dysfunction including, for example, 
investigating genetic risk factors underlying                           
neurodevelopmental disorders such as autism.  SPARK is         
a landmark online research partnership designed to speed        
up our understanding of the causes of 
autism and how autism impacts all those 
affected. 
 
SPARK’s goals are twofold.  First, the  
project will identify the hundreds of    
autism genes at play and link them to the 
biological mechanisms that they govern,  
as well as any environmental factors to 
which those with autism may have been 
exposed.  Second, it seeks to connect these         
individuals and families to research     
opportunities that advance the under-
standing of autism.  
 
Maine Behavioral Healthcare and MMCRI were chosen as the 
clinical site for Northern New England, one of 25 clinical sites 
across the nation. “SPARK is a unique opportunity for people 
in Maine, New Hampshire and Vermont to participate in cut-
ting edge research and receive results from the most advanced  
genetic analysis available,” says Matthew Siegel, M.D., Principal 
Investigator for SPARK Northern New England. 
 
The study is funded by the Simons Foundation Autism       
Research Initiative. This first of its kind study will be done  
entirely online to encourage all in the autism community to 
participate, with the goal of establishing the largest online   
autism research cohort —50,000.  There have been 703       
participants enrolled to date in the SPARK Northern New  
England study. 
 
Since there is no singular cause of autism, there is still much we 
do not know.  The knowledge gained through scientific      
research like SPARK is moving us closer to better understand-
ing the causes of autism and developing effective treatments 
and tools for the everyday challenges autism brings.  For more 
information about SPARK Northern New England see      
sparkforautism.org/mainemedicalcenter. 
   
 
 
Left:  Dr. Siegel is the Principal Investigator for 
SPARK Northern New England, the VP for Medical 
Affairs Developmental Disorders Service Maine 
Behavioral Healthcare, and a Clinical Investigator 
at MMCRI. 
Noteworthy 
Dr. Rago is the Chief Resident for 
Research & Quality Improvement 
in Psychiatry at Maine Medical 
Center (MMC).  She is currently 
the Principal Investigator on a study       
analyzing the efficacy and safety of 
electroconvulsive therapy (ECT) in patients with dementia 
and behavioral disturbance, which is taking place at the   
inpatient Psychiatry Unit (P6) at MMC.  The study began in 
2016 and is funded by a Mentored Research Grant from 
MMCRI.   
 
“In addition to establishing the safety and efficacy of this        
intervention in this population, we anticipate that data     
collected in this observational study will provide insight into 
which patients (with what clinical manifestations) are      
predicted to have a positive response to ECT,” says Dr. Rago. 
“We also hope to inform future discussion of depression in 
patients with dementia.” 
 
Amanda Rago, D.O., 
Principal Investigator 
Susan Santangelo, ScD, Director 
ECT’s Role in Patients 
with Dementia                         
& Behavioral Disturbance 
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The Autism & Developmental Disorders Inpatient Research Collaborative (ADDIRC) is a research consortium of specialized child       
psychiatry in-patient units that serve children and adolescents with autism and developmental disorders.  ADDIRC was launched in 
2013 and is led by Dr. Matthew Siegel and Susan Santangelo.  Until recently, adequate phenotypic and biological data from           
individuals severely affected by autism was lacking.  Now that has changed due to the Autism Inpatient Collection (AIC) phenotypic   
database and biorepository which was created by the ADDIRC and is supported by grants from the Simons Foundation Autism    
Research Initiative and the Nancy Lurie Marks Family Foundation. 
 
Highlights since the launch of ADDIRC & 
AIC: 
 Screened 2172 inpatient youth (499   
patients screened in year 4) 
 1158 Subjects enrolled & 911 Subjects 
with ASD confirmed  
 Biosamples collected from 791 con-
firmed ASD subjects and 916 biological 
parents comprising 194 singletons, 278 proband/parent duos, and 319 trios  
 14 total manuscripts published or in review; 16 conference posters plus 3 recent abstracts submitted 
The study is scheduled to conclude October 2018. For more information about ADDIRC, AIC and a list of Coordinating &                
Participating Site Members go to www.mmcri.org/cpr. 
 
Study Looks at Effects of Earthquakes    
in Nepal 
On April 25, 2015 a magnitude 7.8 earthquake struck Nepal,    
killing more than 8,000 people and injuring over 21,000.  As a 
result, hundreds of thousands of Nepalese were homeless and   
entire villages were flattened in many areas.  Complicating          
matters, on May 12, 2015 the largest aftershock occurred 
(magnitude of 7.4) followed minutes later by a magnitude 6.3 
shock.  More than 450,000 people were displaced overall.    
 
The horrific effects of earthquakes go far beyond immediate      
physical destruction.  It is difficult to imagine the losses both    
physical and mental that can occur during such devastation. 
Until now there was limited knowledge regarding post-
disaster psychopathology, and even mental health in general 
in the Nepali population. Through internal funding, Susan             
Santangelo, the Director of the Center for Psychiatric      
Research at MMCRI, was able to launch the Nepal PTSD 
Project in March 2016.   
 
“The goals of the project are to determine the prevalence of 
PTSD, depression, resilience and factors associated with event impact among earthquake survivors,” says Santangelo. “In addition, we 
trained college students in Skills for Psychological Recovery (SPR) to enable the students to train villagers to ultimately help each other.”  
Currently, data are being analyzed to determine the impact of teaching skills for psychological recovery to the villagers.  
Above: Maine Behavioral Healthcare Trauma experts, Rebecca      
Hoffman-Frances and Rebecca Brown, lead discussion of earthquake 
aftermath with school children. Right: A destroyed home in Nepal and 
Nepalese family outside their temporary home. 
Autism & Developmental Disorders Inpatient Research Collaborative 
(ADDIRC) Update: Autism Inpatient Collection (AIC) 
 12 
 
Center for 
Outcomes Research & Evaluation 
(CORE) 
COMMUNITY—HEALTH SERVICES RESEARCH 
Understanding New Genomic Tumor Tests 
CORE’s focus is on    
conducting innovative 
research to understand 
and improve patient-
centered outcomes in 
healthcare delivery.  In 
2017, CORE received a 
$1.5 million subcontract 
to lead the outcomes     
evaluation for the Maine 
Cancer Genomics       
Initiative (MCGI).  Led by 
the Jackson Laboratory 
(JAX) and supported by 
the Harold Alfond    
Foundation, the MCGI is a 
unique collaboration         
between research and clinical 
institutions to evaluate implementation of precision        
medicine in oncology throughout Maine. 
 
A team at CORE, led by Principal Investigator Dr. Paul Han 
(pictured above), is partnering with the MCGI team at JAX 
(led by Drs. Jens Reuter & Andrey Antov), to study the     
implementation of tumor genomic testing and downstream 
outcomes that will inform the implementation of precision 
medicine in oncology, and develop a sustainable research-
healthcare system partnership model. 
The research aims of the MCGI are: 
 To characterize the feasibility and outcomes of            
implementing tumor genomic testing in oncology      
practice.  
 To understand physician and patient knowledge,        
attitudes, and experiences regarding the implementation 
of tumor genomic testing in oncology practice. 
 
The MCGI has begun recruiting and enrolling patients and 
physician participants at oncology practices throughout the 
state. CORE’s team is working closely with their JAX      
colleagues to carry out the study protocol and collect data 
that will inform the implementation of tumor genomic   
What are the key Components of MCGI? 
Graphic Source:  The Jackson Laboratory 2017 
Dr. Paul Han, Principal Investigator 
for MCGI Grant & MMCRI Director  
of CORE 
sequencing in community settings as precision medicine becomes 
more widely adopted throughout the United States. CORE’s             
multidisciplinary team on the MCGI includes Leo Waterston, MA, 
Sue Miesfeldt, MD, Eric Anderson, PhD, Christine Duarte, PhD, 
Lee Lucas, PhD, Kim Murray, MS, Caitlin Gutheil, MS, and     
Hayley Mandeville, MPH. 
 
“Cancer patients typically get their care at community hospitals, in 
rural or suburban settings, and this is especially true in Maine,” 
says Dr. Han. “The MCGI provides a unique opportunity to      
understand and improve the implementation of emerging genomic 
technologies in community-based settings in Maine and beyond.”  
Paul Han, MD, MA, MPH  Director 
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What are the key Components of MCGI? 
Reducing the Risks of Lung Cancer 
through Prevention & Education                 
Noteworthy  
As part of CORE’s partnerships with the Maine-
Health Center for Performance Improvement and 
the MMC Department of Medical Education,     
Dr. Kathleen Fairfield helped lead the               
development of a new 1-year Certificate in Health 
Improvement, offered jointly through MMC and The         
Dartmouth Institute for Health Policy & Clinical Practice 
(TDI). The MMC-TDI Certificate Program is designed for   
inter-professional teams who are willing to analyze practice 
patterns and population health reports to understand       
improvement opportunities.  These teams will leverage      
partnerships outside traditional boundaries, foster inter-
disciplinary teamwork, and lead the change to improve health 
care delivery and population health. The program’s inaugural 
cohort is currently completing the certificate, with plans for a 
new cohort to enroll every year. 
 
In partnership with the MMC Department of Medical             
Education, CORE is leading the evaluation of the              
(Inter-professional Partnership to Advance Care and         
Education (iPACE) program, an innovative project to       
redesign the clinical learning environment to improve inter-
professional care and  education.  Funded by the “Pursuing 
3 
Paul Han, MD, MA, MPH  Director 
FMI For more information about CORE go to www.mmcri.org/core 
The Maine Lung Cancer Coalition (MLCC) is a 4-year 
statewide, multi-institution, multi-disciplinary        
initiative, begun in August 2016, whose goals include 
improving evidence-based lung cancer prevention, 
early detection, stakeholder engagement and          
education, and research and data analytics to gain a 
better understanding of lung cancer determinants, 
disparities, and outcomes.  MMCRI is the lead       
institution for the Coalition, which is led by Dr. Paul 
Han (Principal Investigator), Dr. Neil Korsen (Co-PI), 
and Leo Waterston (Project Director). The MLCC is 
funded by grants from the Bristol-Myers Squibb   
Foundation and the Maine Cancer Foundation      
totaling $5.4M, and in-kind support was provided by 
the Maine Economic Improvement Fund. The MLCC 
brings together diverse stakeholders across the entire 
state to work together to reduce suffering and death 
from lung cancer, with a special focus on vulnerable 
rural populations with limited access to health care. 
 
The MLCC held its first annual Advisory Board   
meeting in June 2017, at Pineland Farms in New 
Gloucester, Maine. The Advisory Board members  
represent key stakeholder groups in Maine, including 
healthcare providers, legislators, insurers, employers, 
government, and lung cancer survivors. Several MLCC 
consultants also attended the meeting including      
Dr. Jamie Studts, Principal Investigator of the        
Dr. Paul Han, Leo Waterston, and Dr. Jamie Studts (University of Kentucky 
Markey Cancer Center), attend the first annual MLCC  Advisory Board 
meeting in June.  
Excellence” initiative of the Accreditation Council for    
Graduate Medical Education (ACGME), the iPACE program 
aims to optimize patient-centered care; resident engagement 
in patient safety and quality; provider and staff well-being and 
satisfaction; and the efficiency of care and education.  The 
centerpiece of the program is the establishment of a new 18-
bed patient care unit fundamentally redesigned to foster inter-
professional clinical learning and care.  MMC is one of 8 
premier “Pathway  Innovator” institutions in the country that 
was selected to participate in this ACGME 
program. 
 
CORE hosted seven students and trainees 
over the past year, including                 
undergraduate, graduate, medical, and 
postdoctoral trainees from around the 
United States and Europe. These internships and fellowships 
resulted in several peer-reviewed abstracts, publications, and 
presentations at national medical conferences. 
Kentucky LEADS Collaborative, who shared his experience 
leading a similar statewide lung cancer initiative.  
Lung cancer is the leading cancer killer of both men and  
women in the United States, with Maine’s lung cancer rates 
30% higher than the national average.  The MLCC will help 
to change those figures in Maine by developing, implementing 
and evaluating innovative programs to increase access to lung 
cancer prevention and treatment services in Maine, targeting 
rural high-risk populations. 
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COMMUNITY—EDUCATION & RESEARCH SUPPORT 
MMCRI/INBRE CAREER PANEL “Exploring Graduate School and     
Careers in Science, Biomedical & Health Research”, was held on May 30, 
2017, and included an overview of UMaine PhD and USM MPH       
programs, a career panel of 14 professionals, and a tour of MMCRI  
 
RESPONSIBLE CONDUCT OF RESEARCH SERIES  Included: 
“Collaborations in Research”, "Mentoring", “The New England       
Journal  of Medicine Comes to Maine!”, & “Emerging Ethical   
Issues in CRISPR Genome Editing” 
 
FIELD TRIPS HOSTED  Scarborough High School Gifted &         
Talented Program, Greater Portland Christian School Chemistry & 
Biology classes, and several high schools in Central Maine with        
Gifted & Talented programs. 
Lucy Liaw, PhD, Director  
A Q 
An Up Close Look at 
one Student’s Journey 
through MMCRI 
Education & Training 
What is your connection to Maine Medical Center Research 
Institute? 
I first heard about MMCRI in October 
of 2015 when I sat down at a guest   
lecture given by Dr. Lucy Liaw at      
University of  Southern Maine. I had 
enrolled at USM to complete a second 
degree with the eventual aim of applying 
to MD programs. A newcomer to      
science, I had been fascinated by my 
introductory courses like cellular      
biology, physiology and biochemistry. 
The fact that Dr. Liaw’s talk drew on 
concepts from not just one but        
seemingly all of these disciplines sparked 
my curiosity.  I attended MMCRI's open 
house, and a few weeks later was welcomed to the Liaw lab as 
an academic intern. I remained at the Dr. Liaw’s lab for the 
following 18 months in what would prove to be my most   
enriching and exciting academic experience to date. I was  
fortunate enough to work not only as an intern, but          
subsequently as an American Heart Association funded fellow 
and finally a research assistant. In July of 2017 I left MMCRI 
to begin as an MD candidate at Tufts University School of     
Medicine in the Maine Track program. 
 
Why did you seek a research position at MMCRI? 
As I listened to Dr. Liaw's guest lecture in 2015, it dawned on 
me that science is an unending endeavor and that her lab just 
down the road at MMCRI was actively posing and exploring 
new questions about the biology of blood vasculature. I was 
thrilled by the idea that there were thousands of questions still          
unanswered - unasked, even - building upon those             
fundamental concepts I was studying at USM. 
 
What surprised you or was unexpected about working at 
MMCRI? 
I was most surprised and impressed by the spirit of            
mentorship, collaboration, and education guiding the work at 
MMCRI. I returned to academics in 2015 after pursuing a 
career as a journalist in New York, working at various        
television networks over the course of six years.  My           
experience showed me that in many other fields and          
industries work is often siloed and independent.  
At MMCRI, not a day went by without a     
colleague or mentor teaching me a new technique, sharing a         
protocol or reagent, or helping me decipher data. It is that generosity 
of expertise and resources that made my experience at MMCRI   
invaluably enriching as a young student and researcher. 
 
How did the experience influence your professional/career       
ambitions? MMCRI exposed me to a world of biomedical research 
that pushes forward the boundaries of biochemistry, genetics, and 
developmental biology every day. Though I will, one day, practice 
medicine as a specialized clinician, I hope that my career can       
encompass research as a physician scientist. Without my experiences 
at MMCRI, I might never have discovered the joys and rewards of 
scientific research.  
Noteworthy  
Above:  Spencer Scott during his internship in the 
Liaw laboratory prior to his entry into the 
MaineTrack Medical School program.    
Left:  Spencer is welcomed to the TUSM-Maine 
Track program by Dr. Peter Bates. 
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NIH Predoctoral Research Fellowship 
Sarah McCarthy, Oxburgh Lab 
To study factors involved in abnormal 
development of the kidney and help find 
treatment for chronic kidney disease. 
 
NIH Postdoctoral Research Fellowships 
Katie Bishop, PhD, Rosen Lab 
To study the mechanism by which Dock7, 
a novel therapeutic target, promotes bone 
formation and couples bone remodeling in 
order to develop more effective treatments 
for osteoporosis.  
 
Sarah Peterson, MD, PhD Sawyer/Ryzhov Lab 
To investigate the role of Neuregulin/
ERBB3 signaling in resolving the systemic 
inflammatory response following open 
heart surgery.  
 
American Heart Association Postdoctoral 
Fellowship 
Amanda Lessard, PhD ,Sawyer/Ryzhov Lab 
To investigate the role of retinoic acid in 
repair of the adult heart after cardiac   
injury. 
 
American Heart Association Predoctoral          
Fellowship  
Jessica Davis-Knowlton, Liaw Lab 
To investigate the role of vascular smooth 
muscle cell Notch2 on atherogenesis and 
plaque burden. 
 
American Heart Association Mentored 
Clinical and Population Research Award 
Michael Robich, MD 
To study the potential beneficial effects of 
resveratrol on the cardiovascular system 
particularly in patients with diabetes   
mellitus.   
 
NIH Career Development Awards 
Katherine Motyl, PhD 
To determine the neural and skeletal 
mechanisms through which a particular 
protein alters bone and marrow fat      
metabolism. 
 
Elizabeth Rendina-Ruedy, PhD 
To study bone metabolism in patients with 
type 2 diabetes mellitus to better          
understand bone biology which might 
ultimately contribute to the development 
of novel therapies to protect patients from 
diabetic fracture.  
 
Abby Fleisch, MD, MPH 
To investigate preventable early life       
determinants such as prenatal air pollution 
exposure in order to better inform public 
health interventions to improve early  
childhood health.  
 
Teresa May, DO 
To identify cardiac arrest patients at high 
risk of seizure during their ICU stay and 
see if changes in their treatment will help 
their brains heal.  
10   Rotating & Fulltime  
  Graduate Students    
10 Research Fellows 
29 Academic Interns:  
15 different labs & research areas 
2 International Visiting Scholars 
2 MMC Medical Residents 
6 Student Employees 
 
Career Development Awards for 
Young Investigators 
Left:  Humphrey Lotana, a  
student at USM,  participates 
in a  research project as part 
of the SSRP.  
Left: MMCRI’s Summer      
Student Research Program 
(SSRP) Class of 2017. 
Above: Participants in the 
2017-2018 IGNITE ME 
high school biomedical 
research program. 
FACTS &  
FIGURES 
 
Alexa Craig, MD 
To study the safety and efficacy of  delayed 
rewarming in neonates as a post-cardiac 
surgery temperature management strategy 
to improve developmental outcomes.  
 
American Association For the Surgery of 
Trauma Research Education and      
Scholarship Award  
Damien Carter, MD 
To study the application of topical stress 
signaling inhibitor on burned skin areas to 
more effectively treat patients with severe 
burns. 
 
NIH Small Grant Program (R03) 
Anyonya Guntur, PhD 
To better understand the metabolic     
pathways that control lineage allocation 
and identify novel anabolic therapeutic 
targets that may help in treatment of    
osteoporosis. 
MMCRI supports the training and career development of young    
professionals pursuing careers in biomedical research. These           
outstanding young  investigators have been successful in receiving 
recognition and external funding for their research: 
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Enhancing the 
health of our      
population through              
excellence in          
research across the 
spectrum of the    
biomedical and 
health sciences. 
Maine Medical Center Research Institute 
81 Research Drive  ● Scarborough, ME 04074  
Phone: 207-396-8181 ● www.mmcri.org  
Connect with us on 
 
SUPPORT OUR 
RESEARCH 
By donating to MMCRI, you help bring the latest scientific discoveries to 
the bedside and improve the quality of care patients receive. Today’s 
groundbreaking study could be tomorrow’s life-saving treatment. Your 
gift will help support research projects that further our understanding of 
disease processes, which enables us to develop better diagnostics and 
treatment.  
 
Areas of opportunity for support of MMCRI’s laboratory-based or clinical 
research projects include:  Cardiovascular Disease, Cancer, Bone and 
Mineral Disease, Molecular Biology and Genetics, Clinical Trials,         
Psychiatric Research, and Vector Borne Diseases. 
 
Our efforts go beyond research, as well:  by supporting our summer 
scholarships, you will help us educate and cultivate the next generation 
of researchers, and ensure that the quest for knowledge and insight 
continues for years to come.  
 
If you’re interested in supporting the work of Maine Medical Center 
Research Institute, please contact Laura Hellen of the Philanthropy   
Department at (207) 662-5587 or by email at lhellen@mmc.org. 
Cover Photos  Front cover from Dr. Michaela 
Reagan’s lab: mouse bone marrow derived   
mesenchymal stem cells seeded onto silk 
scaffold sponges and differentiated for 1 
month in adipogenic media. Back cover (left) 
from Dr. Leif Oxburgh’s lab:  differentiated 
human iPSC in kidney distal tubule (Brn1  
expression; red) and podocytes (Podocalyxin 
expression; green) after seeding in silk 
scaffold. 
MMCRI is already one of the most innovative          
research organizations in the nation.  
With your help, we can achieve even more.  
